Trevogrumab is an investigational drug not approved by the FDA
Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On April 29, 2025, WeightWatchers announced a pharmacy integration with Eli Lilly and Companys LillyDirect pharmacy provider, Gifthealth
Eligibility typically requires BMI 30 kg/m (or 27 with comorbidities) for weight management use, or T2DM diagnosis for glycemic control indication
By slowly reducing the amount of a drug or substance, people can limit the severity of the withdrawal symptoms that develop when their body tries to adjust to the medication or substances absence
Common reasons Dose too low - may need to increase to therapeutic levels (2.4mg or higher) Not enough time - meaningful results typically take 8-12 weeks at adequate doses Calorie-dense liquid calories bypassing satiety signals - watch smoothies, alcohol, sugary drinks Eating through fullness signals - pay attention to your body's cues Inconsistent dosing schedule - must be same day each week for optimal levels Unrealistic expectations - 1-2 lbs per week is healthy, sustainable weight loss Key Research [1]"Once-weekly cagrilintide for weight management in people with overweight and obesity" Lau DCW et al., 2021 Finding: Phase 2 trial showed cagrilintide at 4.5mg achieved 10.8% weight loss versus 3% with placebo over 26 weeks in 706 participants
It is also found to decrease cardiovascular risks
.png)
